Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 10/20 | 0.46 |
| ▸ | HTR2B | P41595 | 9/20 | 0.46 |
| ▸ | HTR2A | P28223 | 8/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3603535 | 0.99 | ADRB1 (0.47) | ADRB1HTR2CHTR2BHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL3604629 | 0.85 | DDB1 (0.44) | HTR2CHTR2BHTR2AHTR6KHK | |
| Hydrochloric Acid SCHEMBL3605368 | 0.85 | DRD2 (0.48) | ADRB1HTR2CHTR2BHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL3604153 | 0.84 | HTR2C (0.49) | ADRB1HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL3601344 | 0.84 | HTR2A (0.49) | HTR2CHTR2BHTR2AALOX5KHK | |
| Hydrochloric Acid SCHEMBL3599253 | 0.84 | HTR2C (0.42) | HTR2CHTR2BHTR2AHTR6ALOX5 | |
| Hydrochloric Acid SCHEMBL3601864 | 0.84 | ALDH1A1 (0.40) | HTR2CHTR2BHTR2AALOX5KHK | |
| Hydrochloric Acid SCHEMBL3600848 | 0.84 | OPRM1 (0.47) | HTR2CHTR2BHTR2AKHK | |
| Hydrochloric Acid SCHEMBL3611638 | 0.83 | KHK (0.46) | HTR2CHTR2BHTR2AHTR6ALOX5 | |
| Hydrochloric Acid SCHEMBL3602862 | 0.83 | HTR2A (0.48) | HTR2CHTR2BHTR2AALOX5KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | ADRB1 224/4885HTR2C 1/4885HTR2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.